Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Income Tax Expense
Income taxes recognized for the period, including current and deferred tax.
Forte Biosciences, Inc.NASDAQ: FBRX
Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026
Income tax expense remains negative
Q1 FY2026 income tax expense was $373K, compared with $0 a year earlier. Trailing-twelve-month income tax expense was $1.41M.
Context
- Income tax expense increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly income tax expense holds near $373K or moves back toward the trailing-twelve-month quarterly average of $352.5K.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Tax Expense history
USD · from the income statement
- Latest · FY2025
- 1.04M USD
- Year-over-year change
- —
| Period | Period end | Income Tax Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.04M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Income Tax Expense vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.41M USD | — | — | — | |
| LTM Mar 2026 | $168K USD | +38.8% | -62.8% | 0.9% | |
| LTM Mar 2026 | $49K USD | +107.9% | -76.4% | — | |
| LTM Mar 2026 | CHF 5K CHF | +463.9% | — | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $800 USD | — | — | — |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $0 USD | — | — | — |
| Peer median (excluding FBRX) | — | +107.9% | -69.6% | 0.0% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 36K | 0 | 9K | 39K | 64K |
| Gross Profit | (36K) | 0 | (9K) | (39K) | (64K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.85M | 5.59M | 21.86M | 21.19M | 58.25M |
| Selling, General & Admin | 7.63M | 8.3M | 10.62M | 15.37M | 12.41M |
| Operating Expenses | 21.49M | 13.9M | 32.48M | 36.56M | 70.66M |
| Depreciation & Amortization | 36K | 36K | 9K | 39K | 64K |
| EBITDA | (21.67M) | (13.84M) | (31.47M) | (35.44M) | (68.27M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (21.49M) | (13.9M) | (32.49M) | (36.6M) | (70.66M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 1.12M | 1.31M | 2.72M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (222K) | 17K | 1.01M | 1.12M | 2.32M |
| Income Before Tax | (21.71M) | (13.88M) | (31.48M) | (35.48M) | (68.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 1.04M |
| Net Income | (21.71M) | (13.86M) | (31.48M) | (35.48M) | (69.38M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (38.85) | (19.96) | (24.92) | (12.17) | (4.71) |
| EPS (Diluted) | (38.85) | (19.96) | (24.92) | (12.17) | (4.71) |
| Weighted Avg Shares | 558.71K | 695.34K | 1.26M | 2.92M | 147.18M |
| Weighted Avg Shares (Diluted) | 558.71K | 695.34K | 1.26M | 2.92M | 147.18M |
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.